Overview
Cobamamide is one of the active forms of vitamin B12 that is also known as adenosylcobalamin or dibencozide. This drug is available as a nutritional supplement to prevent vitamin B12 deficiency. Vitamin B12 is a collective term for these variously substituted corrinoids. The principal biochemical participants are two coenzyme forms of Vitamin B12 that are produced and activated in two separate cellular compartments: methylcobalamin in the cytosol and adenosylcobalamin in the mitochondria . Vitamin B12 (cyancobalamin, Cbl) has two active co-enzyme forms, methylcobalamin (MeCbl) and adenosylcobalamin (AdCbl). There has been a shift in the treatment of vitamin B12 deficiency such that MeCbl is being extensively used and promoted. This exists despite the fact that both MeCbl and AdCbl are necessary for life and have vastly different metabolic fates and functions. MeCbl is mainly involved along with folate in hematopoiesis and the growth of the brain during childhood. Deficiency of AdCbl disturbs the carbohydrate, fat and amino-acid metabolism, and therefore interferes with the formation of myelin. It is therefore important to treat vitamin B12 deficiency with a combination of MeCbl and AdCbl or hydroxocobalamin or cobalamin . Vitamin B12 has important physiological roles including DNA synthesis, myelin formation in the nervous system, red blood cell formation, as well as fatty acid and amino acid metabolism . Please refer to the entry Vitamin B12 for more information on this entry.
Indication
用于各种原因导致的周围神经病变,对各种神经痛如三叉神经痛、坐骨神经痛、多发性神经炎、神经根炎、神经麻痹均有效;各种原因导致的肝炎、肝硬化;风湿性心脏病、关节炎、肌肉和关节劳损;甲基丙二酸血症、萎缩性胃炎、胃大部切除术患者;巨幼红细胞性贫血、营养不良性贫血、妊娠期贫血、恶性贫血;放射线和药物引起的白细胞减少、口腔溃疡。
Associated Conditions
- Malnutrition
- Vitamin B12 Deficiency
- Weight Loss
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2023/07/13 | Not Applicable | Not yet recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Jaymac Pharma | 64661-650 | ORAL | 50 ug in 1 1 | 6/9/2019 | |
Jaymac Pharma | 64661-793 | ORAL | 50 ug in 1 1 | 7/18/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Cobamamide Capsules | 国药准字H20253418 | 化学药品 | 胶囊剂 | 2/20/2025 | |
Cobamamide Capsules | 国药准字H20249040 | 化学药品 | 胶囊剂 | 10/9/2024 | |
Cobamamide Capsules | 国药准字H20253704 | 化学药品 | 胶囊剂 | 3/25/2025 | |
Cobamamide Capsules | 国药准字H20243489 | 化学药品 | 胶囊剂 | 4/11/2024 | |
Cobamamide Capsules | 国药准字H20253590 | 化学药品 | 胶囊剂 | 3/11/2025 | |
Cobamamide Capsules | 国药准字H20253651 | 化学药品 | 胶囊剂 | 3/18/2025 | |
Cobamamide Capsules | 国药准字H20254021 | 化学药品 | 胶囊剂 | 4/30/2025 | |
Cobamamide Capsules | 国药准字H20254058 | 化学药品 | 胶囊剂 | 4/30/2025 | |
Cobamamide Capsules | 国药准字H20244639 | 化学药品 | 胶囊剂 | 8/5/2024 | |
Cobamamide Capsules | 国药准字H20213912 | 化学药品 | 胶囊剂 | 11/30/2021 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.